Cite

HARVARD Citation

    LoRusso, P. et al. (n.d.). Phase 1 Study of first-in-class dUTPase inhibitor, TAS-114 in combination with capecitabine in patients with advanced solid tumors. European journal of cancer. pp. S119-. [Online]. 
  
Back to record